Patents by Inventor Sergej Michailovic Kiprijanov
Sergej Michailovic Kiprijanov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170051067Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: ApplicationFiled: November 11, 2016Publication date: February 23, 2017Applicant: Cancer Research Technology LimitedInventors: Urs Beat Hagemann, Remko Griep, Herald Reiersen, Sergej Michailovic Kiprijanov
-
Publication number: 20160244527Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: ApplicationFiled: May 11, 2016Publication date: August 25, 2016Applicant: AFFITECH RESEARCH ASInventors: Anita KAVLIE, Sergej Michailovic KIPRIJANOV
-
Publication number: 20150104831Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: ApplicationFiled: October 16, 2014Publication date: April 16, 2015Applicant: AFFITECH RESEARCH ASInventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovic Kiprijanov
-
Publication number: 20140369925Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: ApplicationFiled: May 16, 2014Publication date: December 18, 2014Applicant: AFFITECH RESEARCH ASInventors: Anita Kavlie, Sergej Michailovic Kiprijanov
-
Patent number: 8748107Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: February 10, 2011Date of Patent: June 10, 2014Assignee: Affitech Research ASInventors: Anita Kavlie, Sergej Michailovic Kiprijanov
-
Patent number: 8637017Abstract: Disclosed are antibodies that bind to Epithelial Cell Adhesion Molecule (EpCAM) and display certain advantages over known antibodies which bind to EpCAM, for example, the antibodies of the invention show good affinity, good cross-reactivity profiles and excellent ADCC and CDCC activity. Antibodies comprising specific heavy and light chain CDRs are disclosed. The invention thus relates to these antibodies and all uses thereof, in particular in the treatment of cancer. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer. Advantageous immunoconjugate compositions and methods using the new anti-EpCAM antibodies are also provided.Type: GrantFiled: June 9, 2010Date of Patent: January 28, 2014Assignee: Affitech Research ASInventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus, Jenny Margareta Karlsson, Remko Albert Griep, Sergej Michailovic Kiprijanov
-
Publication number: 20120164161Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: ApplicationFiled: December 7, 2011Publication date: June 28, 2012Applicant: AFFITECH RESEARCH ASInventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovic Kiprijanov
-
Publication number: 20110311449Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: ApplicationFiled: February 10, 2011Publication date: December 22, 2011Applicant: AFFITECH RESEARCH ASInventors: Anita Kavlie, Sergej Michailovic Kiprijanov
-
Publication number: 20100310463Abstract: Disclosed are antibodies that bind to Epithelial Cell Adhesion Molecule (EpCAM) and display certain advantages over known antibodies which bind to EpCAM, for example, the antibodies of the invention show good affinity, good cross-reactivity profiles and excellent ADCC and CDCC activity. Antibodies comprising specific heavy and light chain CDRs are disclosed. The invention thus relates to these antibodies and all uses thereof, in particular in the treatment of cancer. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer. Advantageous immunoconjugate compositions and methods using the new anti-EpCAM antibodies are also provided.Type: ApplicationFiled: June 9, 2010Publication date: December 9, 2010Applicant: AFFITECH RESEARCH ASInventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus, Jenny Margareta Karlsson, Remko Albert Griep, Sergej Michailovic Kiprijanov